Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1991 1
1997 1
1998 3
1999 1
2001 3
2002 2
2003 1
2004 1
2005 2
2006 5
2007 2
2008 3
2009 2
2010 8
2011 11
2012 7
2013 6
2014 9
2015 6
2016 6
2017 8
2018 5
2019 6
2020 11
2021 11
2022 5
2023 9
2024 8
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Results by year

Filters applied: . Clear all
Page 1
Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes.
Medford AJ, Velimirovic M, Gefen Y, Niemierko A, Gerratana L, Davis AA, Clifton K, Keenan J, Podany E, Hensing WL, Reduzzi C, Dai CS, Kiedrowski LA, Spring LM, Ellisen LW, Doebele RC, Cristofanilli M, Getz G, Bardia A. Medford AJ, et al. Among authors: ellisen lw. Breast Cancer Res Treat. 2025 Aug;212(3):437-447. doi: 10.1007/s10549-025-07710-w. Epub 2025 May 29. Breast Cancer Res Treat. 2025. PMID: 40439821 Free PMC article.
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.
Lloyd MR, Chica-Parrado R, Weipert CM, Knepper TC, Podany EL, Napolitano F, Ye D, Lin CC, Uemoto Y, Liao J, Wegrzyn C, Walko CM, Ryan LY, Keenan JC, Medford AJ, Liu SA, Wulf GM, Clifton KK, Ma CX, Han HS, Zhang N, Ellisen LW, Bardia A, Arteaga CL, Hanker AB, Wander SA. Lloyd MR, et al. Among authors: ellisen lw. EBioMedicine. 2025 Jun 26;118:105828. doi: 10.1016/j.ebiom.2025.105828. Online ahead of print. EBioMedicine. 2025. PMID: 40578027 Free article.
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
Abelman RO, Wu B, Barnes H, Medford A, Norden B, Putur A, Bitman E, Thant W, Liu T, Weipert C, Fell G, Spring LM, Wander SA, Moy B, Vidula N, Isakoff SJ, Varkaris A, Juric D, Corcoran RB, Ellisen LW, Bardia A. Abelman RO, et al. Among authors: ellisen lw. Clin Cancer Res. 2025 May 15;31(10):1966-1974. doi: 10.1158/1078-0432.CCR-24-2771. Clin Cancer Res. 2025. PMID: 39745368 Free PMC article.
Epitope Expression Persists in Circulating Tumor Cells as Breast Cancers Acquire Resistance to Antibody Drug Conjugates.
Mishra A, Abelman R, Cunneely Q, Putaturo V, Deshpande AA, Bell R, Seider EM, Xu KH, Shan M, Kelly J, Huang SB, Gopinathan KA, Kikkeri K, Edd JF, Walsh J, Dai CS, Ellisen L, Ting DT, Nieman L, Toner M, Bardia A, Haber DA, Maheswaran S. Mishra A, et al. Among authors: ellisen l. bioRxiv [Preprint]. 2025 Apr 3:2025.04.02.646822. doi: 10.1101/2025.04.02.646822. bioRxiv. 2025. PMID: 40235972 Free PMC article. Preprint.
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
Spring LM, Scarpetti L, Medford AJ, Niemierko A, Comander A, Mulvey T, Schnipper L, Isakoff SJ, Moy B, Wander SA, Shin J, Ephrem Z, Laposta AR, Denault E, Abraham E, Calistro G, Kalashnikova E, Rodriguez A, Liu MC, Aleshin A, Peppercorn J, Ellisen LW, Bardia A. Spring LM, et al. Among authors: ellisen lw. NPJ Breast Cancer. 2025 Jan 7;11(1):2. doi: 10.1038/s41523-024-00708-5. NPJ Breast Cancer. 2025. PMID: 39774684 Free PMC article.
141 results